Closed · W81XWH-15-PCRP-ERA · CFDA 12.420 · Discretionary
DoD Prostate Cancer Exceptional Responders Award
Federal grant opportunity posted by Defense Health Agency Contracting Activity - DHACA, cataloged on Grants.gov.
- Varies
- Award range
- Closed
- Status
- September 24, 2015
- Close date
- 1
- Expected awards
The verdict
DoD Prostate Cancer Exceptional Responders Award is a closed discretionary listing from Defense Health Agency Contracting Activity - DHACA that offered Varies by applicant across 1 expected award. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 1,795 other opportunities from Defense Health Agency Contracting Activity - DHACA.
- Varies
- award range
- Closed
- application status
- 1
- expected award
- 12.420
- CFDA program
Archived opportunity record
DoD Prostate Cancer Exceptional Responders Aw… is closed (last close September 24, 2015). Check the agency catalog for replacement NOFOs. Defense Health Agency Contracting Activity - DHACA still indexes 1,795 other opportunities here.
According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.
Deadline tracker
Application window closed
Closed September 24, 2015
Est. Total Funding
$4,000,000
Expected Awards
1
Instrument
Grant
Description
The PCRP Exceptional Responders Award (ERA) mechanism is being offered for the first time in FY15. This award supports a research effort conducted by leading prostate cancer researchers that specifically focuses on identifying and understanding predictors of disease outcomes in exceptional responders to prostate cancer therapies. Research projects proposed under the ERA can be either discovery or target-driven but must include an in-depth examination of outlier responses to prostate cancer therapy that will lead to significant improvements to the clinical management of prostate cancer. The research project should address overarching issues that have broad implications for the disease and risk management, such as risk factors at the individual level and systems level, treatment, toxicity, and dormancy. The research project should not focus merely on the study of specific molecular pathways or genes, but should be focused on identifying what is unique to exceptional responders, which may include biological, behavioral, or other lifestyle factors. It is expected that inclusion and exclusion criteria for identifying Exceptional Responders, including the specific type of therapy/therapies being addressed, will be clearly defined in the application. The PCRP encourages inclusion of any form of prostate cancer therapy that produces a disparate response in treated patients, although projects addressing exceptional responses to androgen deprivation therapies are particularly encouraged. All projects proposed for the ERA are required to address one of the PCRP overarching challenges and the PCRP focus area of Mechanisms of Resistance. However, it is expected that applications will address more than one focus area.
Catch-all / unrestricted eligibility mark · W81XWH-15-PCRP-ERA
Grants.gov marks DoD Prostate Cancer Exceptional Responders Aw… with a catch-all / unrestricted eligibility code (Unrestricted / see official listing). Read the official announcement text for the real applicant filter — the code alone is not a door list. The extract does not mark applicant cost-sharing as required. Instrument: Grant. Funding-activity code maps to Science and Technology / R&D (ST). This eligibility-code string dominates the Defense Health Agency Contracting Activity - DHACA book (1,791 peers, 100% of 1,796).
- Code 99
- Unrestricted / see official listing
Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Agency Contact
CDMRP Help Desk 301-682-5507
More from Defense Health Agency Contracting Activity - DHACA
DoW Neurofibromatosis Synergistic Idea Award
DoW Neurofibromatosis Investigator-Initiated Research Award
DoW Neurofibromatosis Research Academy – Scholar Award
DoW Neurofibromatosis Exploration-Hypothesis Development Award
DOW Combat Readiness – Medical Research Program Translational Research Award
What to do next
DoD Prostate Cancer Exceptional Responders Aw… is closed; use the parent program and agency catalog for the next funding cycle.
- Browse open federal opportunities in the same category when this listing is closed. Open opportunities
- Look up CFDA 12.420 across all indexed listings before you commit to this opportunity alone. Eligibility finder
- Compare award ranges across federal categories before you pick a single CFDA. All categories
Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |